Corvus Corporate Presentation March 2022

An immunology focused company developing drugs and antibodies that target the most critical cellular elements of the immune system



Forward-Looking Statements / Safe Harbor



2

This presentation and the accompanying oral presentation contain "forward-looking" statements, including statements related to the potential safety and efficacy of mupadolimab, CPI-818 and ciforadenant; the Company's ability and Angel Pharmaceutical's ability to develop and advance product candidates into and successfully complete preclinical studies and clinical trials, including the Company's planned Phase 2 clinical trial of mupadolimab, the Company and Angel's Phase 1/1b clinical trials of CPI-818 as well as a potential global phase 2 study clinical trial in advanced PTCL, and the Company's plan to initiate a Phase 2 clinical trial with ciforadenant in collaboration with the Kidney Cancer Clinical Trials Consortium, the timing of the availability and announcement of clinical data and certain other product development milestones, including the timing of initial results in the Phase 1b/2 clinical trial for mupadolimab. All statements other than statements of historical fact contained in this press release are forward-looking statements. These statements often include words such as "believe," "expect," "anticipate," "intend," "plan," "estimate," "seek," "will," "may" or similar expressions. Forward-looking statements are subject to a number of risks and uncertainties, many of which involve factors or circumstances that are beyond the Company's control. The Company's actual results could differ materially from those stated or implied in forward-looking statements due to a number of factors, including but not limited to, risks detailed in the Company's Annual Report on Form 10-K for the year ended December 31, 2021, filed with the Securities and Exchange Commission on or about March 10, 2022, as well as other documents that may be filed by the Company from time to time with the Securities and Exchange Commission. In particular, the following factors, among others, could cause results to differ materially from those expressed or implied by such forward-looking statements: the Company's ability to demonstrate sufficient evidence of efficacy and safety in its clinical trials of mupadolimab, CPI-818 and ciforadenant; the accuracy of the Company's estimates relating to its ability to initiate and/or complete preclinical studies and clinical trials; the results of preclinical studies may not be predictive of future results; the unpredictability of the regulatory process; regulatory developments in the United States, and other foreign countries; regulatory developments in the United States, and other foreign countries; the costs of clinical trials may exceed expectations; the Company's ability to accurately estimate the amount of net cash used in operating activities for 2022; and the Company's ability to raise additional capital. Although the Company believes that the expectations reflected in the forwardlooking statements are reasonable, it cannot guarantee that the events and circumstances reflected in the forward-looking statements will be achieved or occur, and the timing of events and circumstances and actual results could differ materially from those projected in the forwardlooking statements. Accordingly, you should not place undue reliance on these forward-looking statements. All such statements speak only as of the date made, and the Company undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise. The Company's results for the guarter and year ended December 31, 2021 are not necessarily indicative of its operating results for any future periods.

This presentation concerns products that are under clinical investigation and which have not yet been approved for marketing by the U.S. Food and Drug Administration. Such products are currently limited by Federal law to investigational use, and no representation is made as to its safety or effectiveness for the purposes for which it is being investigated.

Advancing Three Clinical Programs



Mupadolimab

Differentiated anti-CD73 antibody

Plan to initiate Randomized Phase 2 study in frontline nonsmall cell lung cancer (NSCLC) in 2H 2022

Data from Phase 1b/2 expansion cohorts (NSCLC and HNSCC) anticipated in 2H 2022

CPI-818

Angel Pharmaceuticals currently enrolling Phase 1/1b study in China

Angel is responsible for all expenses related to executing the trial in China

Corvus enrolling Phase 1/1b study in U.S.

Data from Phase 1/1b studies anticipated in 2H 2022

Ciforadenant

Plan to initiate Phase 1b/2 study in frontline renal cell cancer (RCC) in 2Q 2022

Collaboration with Kidney Cancer Clinical Trials Consortium provides partial funding and inclusion of leading sites

Data from Phase 1b/2 study anticipated in 2022



Target	Indication	DEVELOPMENT STATUS				
		Lead Optimization	IND-Enabling	Phase 1/1b	Phase 1b/2	Phase 3
B Cell Activator &	NSCLC	Mupadolimab (CPI-006)				
Anti-CD73	HNSCC	Mupadolimab (CPI-006)				
ITK Inhibitor	T-cell lymphoma	CPI-818				
	Angel Pharma	CPI-818				
A2AR Inhibitor	Renal cell cancer	Ciforadenant				
Anti-CXCR2	Multiple cancers	CPI-182				
	Inflammation	CPI-182				
A2BR Inhibitor	Fibrosis	CPI-935				

Mupadolimab Anti-CD73 with B cell activating properties



B cells - Important Predictors of IO Response and Prognosis



- B cells are found in tumors of responders^{1,2,3}
- The B lineage signature in tumors was the dominant parameter for overall survival²
- Activated B cells and antibody secreting cells specific for tumorspecific antigens found in the tumor microenvironment in HPV⁺ head and neck patient samples^{4,5}
- High density B cells within tertiary lymphoid structure promote CD4+ T cell response and are associated with superior clinical outcomes in NSCLC patients^{6,7}

1. Helmink et al, Nature, 2020; 2. Petitprez et al, Nature 2020; 3. Cabrita et al, Nature 2020; 4. Weiland et al, Nature 2020; 5. Ruffin et al, Nat. Commun. 2021; 6. Germain et al, Am. J. Respir. Crit. Care. Med. 2014; 7. Germain et al, Front Immunol. 2021


Corvus is a Leader with a Differentiated Antibody Anti-CD73 competitive landscape




Company	Program	Adenosine Blockade	B Cell Activation	Status
CORVUS PHARMACEUTICALS	Mupadolimab	Full	Strong*	Phase 2/3 ready
AstraZeneca	Oleclumab	Partial	Weak	Phase 2
BIOPHARMA / TRACON	Uliledlimab	Full	Moderate	Phase 1
ر <mark>الا،</mark> Bristol Myers Squibb	BMS-986179	Partial	Not reported	Phase 1
UNOVARTIS / SURFACE ONCOLOGY	NZV930	Partial	Not reported	Phase 1
Incyte	INCA00186	Partial	Not reported	Preclinical

* Also shown to activate T cells and antigen presenting cells

Mupadolimab is an Anti-CD73 Antibody with Dual Function B cell activation and adenosine blockade







B Cell Activation & Differentiation

- Mupadolimab activates B cells, resulting in morphological and surface marker changes consistent with B cell differentiation
- Comparison to adenosine blocking anti-CD73 antibody oleclumab demonstrates potent B cell stimulation

Targeting B Cells and T Cells: Mupa, anti-PD(L)1 Combo Step on the gas and release the brake...



ORVUS






- 189 patients with unresectable, stage III NSCLC were randomized in COAST Phase 2 trial
- Addition of oleclumab (CD73 antibody) to durvalumab (PD-L1 antibody) improve clinical outcome over durvalumab alone in frontline treatment
 - Durvalumab in combination with oleclumab reduced risk of disease progression or death by 56%
 - Increase in ORR for oleclumab plus durvalumab over duravalumab (38.3% vs 25.4%)
- Corvus' expansion cohort is ongoing in patients with NSCLC and head and neck cancer

ITT	Durvalumab	Duravalumab + Oleclumab
Ν	67	60
ORR (95% Cl), %	25.4 (15.5, 37.5)	38.3 (26.1, 51.8)
Median PFS (95% Cl), %	6.3 (3.7, 11.2)	NR (10.4, NE)
PFS HR (95% Cl)	-	0.44 (0.26, 0.75)

Mupadolimab Phase 1 Study CPI-006-001





Design

- Phase 1/1b dose escalation/dose expansion in disease specific cohorts
- 3+3 design for dose escalation

Eligibility


• Cancers progressed on 1-5 prior therapies

Objectives

- Primary: Safety and tolerability
- Secondary: PK/PD, efficacy, biomarkers

Currently enrolling HNSCC & NSCLC in mupa + pembro


SITC Data: Anti-tumor Activity in Pts with ≥12 mg/kg Tumor regression in pts with PD as best response to prior therapy



[•] Cifo = ciforadenent (A2AR antagonist), pembro = pembrolizumab (anti-PD-1), atezo = atezolizumab (anti-PD-L1), bev = bevacizumab (anti-VEGF), chemo = chemotherapy, nivo = nivolumab (anti-PD-1)

• PD = progressive disease; SD = stable disease; PR = partial response

Mupadolimab Oncology Clinical Trials Expansion in NSCLC and Head and Neck Cancer



Cancers progressed on 1-5 prior therapies ٠


Objectives

- Primary: Safety and tolerability
- Secondary: PK/PD, efficacy, biomarkers ٠

HNSCC

Failed anti-PD1 and chemo

Randomized Phase 2 Trial Design Front-line NSCLC




* Non squamous: carboplatin + pemetrexed; Squamous: carboplatin + paclitaxel

Primary Endpoint	Progression free survival (PFS)
Secondary Endpoints	 Objective response rate (ORR) Duration of Objective Response (DOR) Overall survival (OS) Safety and tolerability

ORVUS

Mupadolimab Anti-CD73 Unique Opportunity




Mupadolimab may overcome resistance to anti-PD(L)1 therapies




Phase 2 randomized (combination with anti-PD-1) in front line NSCLC in Q3 2022

ITK Inhibitor for T Cell Lymphoma and Autoimmunity CPI-818 is a first in class therapy









The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy *PNAS 2010*

Lee A. Honigberg^{a,1}, Ashley M. Smith^{a,1}, Mint Sirisawad^a, Erik Verner^a, David Loury^a, Betty Chang^a, Shyr Li^{b,c}, Zhengying Pan^{b,d}, Douglas H. Thamm^e, Richard A. Miller^{a,f}, and Joseph J. Buggy^{a,2}

CPI-818 Demonstrated Selective Blocking of T cell Function Potential therapeutic for lymphoma and autoimmune disease








CPI-818 ITK Inhibitor Objective responses in Peripheral T Cell Lymphoma






Week 30 PET



American Society of Hematology 2020

ORR: 28% (N=7) 1CR: 15+ months 1PR: 5+ months



Treatment Cycles

Corvus Angel Global Trial in T Cell Lymphomas IND approved and enrolling patients



Corvus Pharmaceuticals

- CPI-818 Phase 1 data
 - Enrolling Patients

Angel Pharmaceuticals

• Enrolling patients

PTCL in China is 26% of non-Hodgkin's lymphoma - more common than in the US

Ciforadenant A2A Inhibitor in Renal Cell Cancer Cancer Discovery January 2020 - Publication & Editorial



Published OnlineFirst November 15, 2019; DOI: 10.1158/2159-8290.CD-19-0980

RESEARCH ARTICLE

Adenosine 2A Receptor Blockade as an Immunotherapy for Treatment-Refractory Renal Cell Cancer Se Section 2015

Lawrence Fong¹, Andrew Hotson², John D. Powderly³, Mario Sznol⁴, Rebecca S. Heist⁵, Toni K. Choueiri⁶, Saby George⁷, Brett G.M. Hughes⁸, Matthew D. Hellmann⁹, Dale R. Shepard¹⁰, Brian I. Rini¹⁰, Shivaani Kummar¹¹, Amy M. Weise¹², Matthew J. Riese¹³, Ben Markman¹⁴, Leisha A. Emens¹⁵, Daruka Mahadevan¹⁶, Jason J. Luke¹⁷, Ginna Laport², Joshua D. Brody¹⁸, Leonel Hernandez-Aya¹⁹, Philip Bonomi²⁰, Jonathan W. Goldman²¹, Lyudmyla Berim²², Daniel J. Renouf²³, Rachel A. Goodwin²⁴, Brian Munneke², Po Y. Ho², Jessica Hsieh², Ian McCaffery², Long Kwei², Stephen B. Willingham², and Richard A. Miller²

VIEWS

IN THE SPOTLIGHT

Lessons from the A2A Adenosine Receptor Antagonist-Enabled Tumor Regression and Survival in Patients with Treatment-Refractory Renal Cell Cancer

Michail V. Sitkovsky

Summary: In this issue of *Cancer Discovery*, Fong and colleagues describe the encouraging observations of tumor regression, disease control, and survival of patients with otherwise refractory renal cell cancer with progressive disease after treatment with the conceptually novel oral antagonist of the A2A adenosine receptor (A2AR), ciforadenat. A2AR antagonists may represent the until now missing but critically important part of more effective immunotherapies of cancer, because they prevent the inhibition of tumor-reactive T and natural killer cells by blocking the immunosuppressive hypoxia-A2A-adenosinergic signaling, which represents an emerging immuno-suppressive hallmark of tumors that are the most resistant to therapies.

See related article by Fong et al., p. 40 (1).

"Fong and colleagues describe... tumor regression, disease control, and survival of patients with otherwise refractory renal cell cancer with progressive disease after treatment with the conceptually novel.... ciforadenant."


"Fong and colleagues are among the first clinical development teams that aimed to block not only the immunologic negative regulators, but also the powerful A2Aadenosinergic negative regulators of antitumor immunity."

¹U Ca Bic Ca Ge Fa

Currently, the majority of patients with cancer are still eventually refractory to any cancer therapy despite a massive and decades-long effort. The hope for the solution to this

misguidedly protects the hypoxic and extracellular adenosinerich cancerous tissues (3, 4, 7). This is why A2AR blockade with synthetic A2AR antagonists has been proposed for a long time


Renal Cell Cancer Response to Treatment



CT26 Preclinical Model Established Tumor

(Willingham et al, Cancer Imm Res. 2018)

CheckMate 214 Trial (Motzer et al, J. Immunother. Cancer, 2020)




Days since engraftment

Triplet Cifo, anti-PD1, anti-CTLA4 cures most animals


4-year follow-up from CheckMate 214 study of IPI/NIVO showing a tail on the curve suggesting potential cures

Phase 2 Trial Design in Frontline RCC





Significant Near-Term Opportunities



- Differentiated anti-CD73 mAb
- Potential broad applications in cancer
- O Phase 2 trial front line to start in Q3 '22
- Corvus/Angel Pharmaceuticals Phase 2 study
 Activity in PTCL seen in refractory patients
- Safety, biomarker and significant clinical experience
 Collaboration with Kidney Cancer Consortium
 Phase 2 trial in front-line RCC planned for Q2 '22